Trump Will Sign “The Right to Try Act of 2017” for Terminally Ill Patients
WASHINGTON — May 31, 2018
Congress passed “the Right to Try Act of 2017” allowing certain unapproved, experimental drugs for terminally ill patients. It will be handed over to President Donald J. Trump for his signature.
Earlier Trump said by himself “People who are terminally ill should not have to go from country to country to seek a cure — I want to give them a chance right here at home.”
Its adoption means resolutions in experimental drugs to be administered to terminally ill patients who have exhausted all approved treatment options and are unable to participate in clinical drug trials.
Also, now any manufacturer or sponsors of an eligible investigational drug have to report to the FDA about use of the drug on a “Right to Try” basis. The FDA in its turn will post an annual summary report of “Right to Try” use on its website.
According to bill, “Right to Try” gives the over 1 million Americans who die of a terminal illness every year a new tool to fight and make potentially life saving decisions about their treatment.
It gives them the right to make healthcare choices that could save their lives.
According to the National Cancer Institute, more 600,000 Americans can die from cancer alone in 2018. Many terminally ill patients were considered too sick for clinical trials of new medication. In fact, only 3 percent of cancer patients today are enrolled in clinical trials.
Apart from, on May 11, 2018, the President issued his blueprint to lower prescription drug prices, taking action to put American patients first.
In March 2018, President Trump’s Administration released the President’s plan to put patients back in charge of their own health information.